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Abstract: Mesalamine and its derivatives are effective and well-tolerated therapies for ulcerative 
colitis. However, patient adherence to traditional mesalamine-based therapy is poor, and is often 
limited by heavy pill burdens and frequent dosing intervals. This can lead to ineffective disease 
control, impaired quality of life, and preventable morbidity and mortality. Previous studies have 
suggested that a once-daily mesalamine regimen would be strongly adhered to in the outpatient 
setting, but at that time no such formulation of mesalamine existed. In 2007, clinical trial data 
showed a novel, once-daily, multi-matrix (MMX) formulation of mesalamine to be effective 
in both remission induction and remission maintenance. This breakthrough in drug delivery 
allowed the uniﬁ  cation of an effective therapeutic with a formulation that enables outpatients to 
be increasingly adherent to their medication. In theory, this might result in improved outpatient 
disease control and a decreased number of ﬂ  ares. As the use of MMX mesalamine increases, 
studies examining the outpatient community adherence rate need to be performed.
Keywords: mesalamine, MMX, Lialda™, ulcerative colitis, inﬂ  ammatory bowel disease, 
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Introduction to management issues in ulcerative 
colitis, patient considerations
Ulcerative colitis (UC) is a chronic inﬂ  ammatory bowel disorder of indeterminate 
etiology characterized by inﬂ  ammation limited to the colonic mucosa. The disease 
can affect small portions, extensive segments, or the entirety of the large intestine. 
Symptoms can include diarrhea that may be bloody, abdominal pain, cramping, as 
well as numerous “extra-intestinal” manifestations. The natural history of UC is one 
of chronic relapse and remission, with a disease course marked by periods of relative 
quiescence punctuated by occasional ﬂ  ares. UC ﬂ  ares are typiﬁ  ed by acute onset of 
increased stool frequency, low-grade fevers, grossly bloody bowel movements, and 
often debilitating abdominal pain. Patients with UC also have a well-described predis-
position towards the development of colorectal cancer.1 It is clear from an extensive 
body of literature that poorly controlled UC has a signiﬁ  cant impact on patient quality 
of life, with extensive associated morbidity and even mortality.2–4
Effective therapy for UC necessitates a two-pronged approach. Standard treatment 
includes a daily maintenance medication regimen for those patients in whom disease 
is quiescent. However, equally as crucial is acute “induction-of-remission” therapy 
for patients experiencing disease ﬂ  ares. For over 50 years, the 5-aminosalicylate 
(5-ASA) agents have been successfully used in both maintenance-of-remission as well 
as in the induction-of-remission during UC ﬂ  ares. Even today, these drugs and their 
derivatives are still considered ﬁ  rst line therapy due to their efﬁ  cacy, favorable side 
effect and safety proﬁ  les, and relatively low cost.5 However, a longstanding obstacle Patient Preference and Adherence 2009:3 88
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to effective UC treatment has been the heavy pill burden 
mandated by 5-ASA therapy, and the resultant difﬁ  culties 
with adherence to treatment regimens. Historically, patients 
with UC ﬂ  ares might be expected to take up to 16 pills on a 
daily basis.6 Recent studies have alerted clinicians to the low 
levels of adherence in outpatient UC treatment,7,8 and have 
pushed researchers towards development of an effective yet 
manageable outpatient treatment paradigm.
In 2007, a once-daily formulation of oral 5-ASA, MMX 
mesalamine (LialdaTM; Shire Pharmaceuticals Inc., Wayne, 
PA, USA) was approved in the USA by the Food and Drug 
Administration for the induction-of-remission in mild-to-
moderate UC. Approval was based on multiple randomized 
controlled trials9–11 that demonstrated a signiﬁ  cant response 
rate compared to placebo, as measured by number of patients 
achieving both a complete clinical and endoscopic remission 
of their UC ﬂ  are. However, the role of MMX mesalamine in 
maintenance-of-remission remained unclear.
More recent follow-up data suggest that once- or twice-
daily therapy with MMX mesalamine is as effective as 
previous 5-ASA formulations for maintenance of clinical 
and endoscopic remission in UC, measured out to one year 
of follow-up.12 Although adherence rates in this study were 
impressive, they were nonetheless achieved in a controlled 
setting well known to artiﬁ  cially inﬂ  ate such results. It still 
remains to be seen whether outpatients with UC will be 
equally adherent to a decreased dosing frequency. If so, this 
may represent a signiﬁ  cant advance for patients whose adher-
ence to therapy, and consequently whose disease control, is 
tied to lower pill burden and simpler dosing regimens.
Review of formulation, pharmacology, 
mode of action, pharmacokinetics 
of MMX mesalamine
MMX mesalamine is a novel formulation of mesalamine that 
delivers a large dose of 5-ASA (1.2 g per pill) in a unique multi-
matrix system (MMX). The exact mechanism of action of 5-ASA 
is not entirely understood, but it is believed to work through 
downregulation of several independent pro-inﬂ  ammatory cel-
lular cascades, thereby limiting the development of intestinal 
inﬂ  ammatory responses.5 These pathways include, but are 
not limited to, the cyclooxygenase (COX) and lipoxygenase 
pathways, which produce inﬂ  ammatory cytokines such as 
prostaglandins and leukotrienes. Other proposed mechanisms of 
5-ASA include inhibition of both TNF-alpha as well as the intra-
nuclear pro-inﬂ  ammatory transcription factor NF-kappaB.13
The introduction of MMX technology allows improved 
and targeted drug delivery throughout the terminal ileum 
and entire colon. MMX mesalamine features an outer 
pH-dependent coating that serves to protect the inner 
multimatrix core until exposed to a pH of above 7.0.14–16 This 
protects the tablet core from gastric milieu and allows it to 
remain intact until entering the terminal ileum. There, the outer 
coating dissolves and exposes the core, which is composed 
of both hydrophilic and lipophilic matrices. When exposed to 
ileal intestinal ﬂ  uid, the core swells up due to its hydrophilic 
component, forming an outer viscous gel mass, and diffusion 
of 5-ASA begins to occur. The diffusion rate might be too 
rapid to allow for drug delivery throughout the entire colon 
were it not for the lipophilic matrix component of the core. It 
is thought that the lipophilic matrix slows the entrance of water 
to the tablet core, resulting in a constantly evolving surface gel 
mass and slower diffusion of 5-ASA from the tablet core to 
the surface, where it eventually breaks off into small pieces, 
delivering 5-ASA to the colonic mucosa.14–16
Pharmacokinetic studies have shown that approximately 
80% of the 5-ASA in MMX mesalamine is absorbed in the 
colon, while the remaining 20% is absorbed in the terminal 
ileum.15 Its overall bioavailability is approximately 20%, 
similar to other 5-ASA compounds.17–19 Once absorbed, 
MMX mesalamine is converted to its major inactive 
metabolite, N-acetyl-5-ASA, by acetyltransferase enzymes 
in the intestinal epithelium and the liver.20 The drug is then 
eliminated in equal proportions by the stool, via direct 
secretion back into the gastrointestinal lumen, and by the 
kidneys, which secrete the hepatically metabolized 5-ASA 
into the urine.5,21 The half-life of 5-ASA is 7 to 9 hours, and 
consequently 4 to 5 days are required to achieve steady-state 
plasma concentrations.
Efﬁ  cacy studies, including 
any comparative studies
Published in 2007, two sister clinical trials, each a 
Phase III, randomized, double-blinded, multi-national, 
placebo-controlled trial, examined the efﬁ  cacy and safety 
of MMX mesalamine.9,10 They independently showed that 
MMX mesalamine, in either once- or twice-daily dosing, 
was effective for induction-of-remission in ﬂ  ares of mild-
to-moderate UC. An open-label follow-up study was also 
performed in order to examine the long-term efﬁ  cacy and 
safety of MMX mesalamine in the maintenance of clinical 
and endoscopic remission.
In the ﬁ  rst of the sister trials, Lichtenstein et al randomized 
280 patients with active mild-to-moderate UC to receive 
placebo, MMX mesalamine 2.4 g per day (divided into 
1.2 g twice-daily dosing), or MMX mesalamine 4.8 g per day Patient Preference and Adherence 2009:3 89
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(dosed in its entirety once-daily).9 Exclusion criteria included 
patients with severe UC, an ongoing refractory relapse lasting 
more than 6 weeks, evidence of prior mesalamine treatment 
failure, and recent steroid, other immunosuppressant, or 
antibiotic use. The primary endpoint was clinical and 
endoscopic remission after 8 weeks of therapy. Initial disease 
severity and remission were measured by a modiﬁ  ed version of 
the Ulcerative Colitis Disease Activity Index (UC-DAI). The 
author’s modiﬁ  cation of the UC-DAI rendered the deﬁ  nition 
of remission even more stringent than usual, meaning that in 
order to have achieved remission in this study, patients needed 
to meet more rigid clinical and endoscopic criteria, such as 
three consecutive symptom-free days as well as absence of 
mucosal friability on sigmoidoscopy. Signiﬁ  cantly more 
patients treated with MMX mesalamine 2.4 g per day or 4.8 g 
per day achieved both clinical and endoscopic remission at the 
end of 8 weeks as compared to placebo (34.1% vs 29.2% vs 
12.9%, respectively). Median time to clinical remission was 
also signiﬁ  cantly improved in the treatment groups. Analysis 
of additional secondary endpoints demonstrated signiﬁ  cant 
improvements in the number of patients who experienced 
clinical remission or sigmoidoscopic remission alone, as well 
as fewer treatment failures after 8 weeks.
The second sister trial, published by Kamm et al, featured 
a near-identical study design, with the addition of a reference 
arm of patients who received conventional delayed-release 
oral mesalamine (Asacol®; Proctor and Gamble, Cincinnati, 
OH, USA) thrice-daily.10 Also, the MMX mesalamine in this 
trial was dosed at either 4.8 g per day or 2.4 g per day, all 
delivered in one undivided daily dose. Overall, 343 patients 
were randomized. Inclusion and exclusion criteria, methods, 
primary and secondary endpoints, and measures of disease 
severity were essentially identical to the sister trial. This 
trial also revealed a signiﬁ  cant improvement in clinical and 
endoscopic remission rates after 8 weeks of 2.4 g per day or 
4.8 g per day of MMX mesalamine therapy as compared to 
placebo (40.5%, 41.2%, and 22.1%, respectively). Subgroup 
analysis conﬁ  rmed a signiﬁ  cant beneﬁ  t in patients receiving 
MMX mesalamine regardless of severity (mild vs moderate) 
or extent of disease (left-sided vs pancolitis). Interestingly, 
the reference Asacol arm showed no signiﬁ  cant improvement 
in clinical and endoscopic remission rates when compared 
to placebo (32.6% vs 22.1%, p = 0.124). This stands in 
contrast to conclusions from previous literature, most notably 
the ASCEND trials, where Asacol was demonstrated to be 
an effective therapeutic in moderately active UC.22,23 It is 
possible that the current study was underpowered to detect 
a signiﬁ  cant difference in the Asacol arm.
At the completion of the above trials, patients who did 
not achieve both clinical and endoscopic remission were 
allowed to enroll in an acute extension trial of once-daily, 
high dose (4.8 g per day) MMX mesalamine for an additional 
8 weeks.24 Of the 304 patients who opted for this treatment, 
59.5% achieved clinical and endoscopic remission after 
8 weeks. This suggested that prolonged, high-dose MMX 
mesalamine might be an alternative to “step-up” therapies 
such as immunosuppressants and/or steroids.
Patients from all three studies who achieved clinical and 
endoscopic remission were allowed to enroll in a randomized, 
open-label, multicenter, one-year follow-up study to examine 
the ability of MMX mesalamine to maintain remission in 
mild-to-moderate UC.12 In addition, a number of patients 
(n = 89) who had not met the strict remission criteria, but who 
were deemed to be in good enough health at the conclusion 
of the prior studies, were also allowed to enroll. In total, this 
trial examined 459 patients and randomized them to receive 
either MMX mesalamine 2.4 g per day (given once-daily) or 
MMX mesalamine 2.4 g per day (given as 1.2 g twice-daily). 
There was no placebo group, as it was considered unethical 
given the clear effectiveness of 5-ASA compounds in main-
taining UC remission. Inclusion and exclusion criteria were 
predeﬁ  ned based on the outcomes from the prior parent trials. 
The primary outcome measure was assessment of safety and 
tolerability, with a secondary objective being comparison of 
remission rates between the two treatment groups.
In terms of safety and tolerability, results showed no 
signiﬁ  cant difference in mean duration of drug exposure 
(mean = 47 weeks), number, type, or severity of adverse 
event, time to withdrawal, or any other measured performance 
characteristic such as vital signs or laboratory testing.12 
Overall adverse event rates were similar to placebo rates 
from established trials.25,26 These results point towards a 
long-term safety proﬁ  le for MMX mesalamine which mirrors 
other 5-ASA compounds.
In terms of efﬁ  cacy, the year-long administration of MMX 
mesalamine in either once- or twice-daily dosing was equally 
effective in maintaining clinical and endoscopic remission 
(64.4% vs 68.5% respectively, p = 0.351). These results are 
in keeping with the majority of published remission rates for 
conventional oral 5-ASA treatments.22,27 As might be expected, 
results varied impressively depending on whether the patient 
enrolled directly from the parent trials, or whether they 
necessitated an additional 8 weeks of high-dose mesalamine 
therapy prior to achieving remission. Patients who required 
the additional therapy were significantly less likely to 
be in remission after 12 months of maintenance therapy Patient Preference and Adherence 2009:3 90
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(56% vs 76%, p  0.0001). This argues that patients who 
were more responsive to MMX mesalamine for induction-
of-remission were likely to respond to MMX mesalamine 
when used for maintenance therapy.
Also not unexpectedly, subjects who did not meet the 
initial stringent remission criteria, but who were nonetheless 
added to the study after being deemed well enough by their 
doctor (“intention-to-treat” subjects), did worse. These 
89 additional subjects had remission rates that were lower 
than the intention-to-treat group as a whole, which also 
included the “per-protocol” subjects. Once- or twice-daily 
MMX mesalamine dosing in these 89 patients did not result 
in a signiﬁ  cant difference in remission rate (52.1% vs 51.2%, 
respectively).12
However, when the entire intention-to-treat data were 
compared to the per-protocol population data, there was no 
signiﬁ  cant difference in remission rate. This points towards 
the conclusion that even patients who do not endoscopically 
respond to induction-of-remission therapy with MMX 
mesalamine, but who still achieve clinical remission and 
are deemed “well” by their clinician, can reasonably hope 
to achieve clinical and endoscopic remission when receiving 
2.4 g per day of maintenance MMX mesalamine.12
Safety and tolerability
5-ASA compounds have the distinct advantage of over a 
half-century’s worth of study and re-formulation in attempts to 
improve drug safety and tolerability. Initial formulations such 
as sulfasalazine, which contains a sulfapyridine moiety linked 
to the 5-ASA via an azo bond, had a higher rate of adverse 
events (AEs) that directly correlated with overall exposure to 
the sulfa moiety.28 However, sulfa-free formulations of 5-ASA 
are better tolerated. In fact, it has been shown that up to 90% 
of patients who stopped taking sulfasalazine due to its side 
effects were able to tolerate 5-ASA.5,22
Multiple trials, including a large meta-analysis, have 
demonstrated that 5-ASA preparations, including MMX 
mesalamine, have a rate of AEs similar to placebo.9,10,29,30 
In a phase II dose-ranging study, MMX mesalamine was 
well-tolerated at all studied doses, with a low incidence of 
AEs consistent with the known safety proﬁ  le of 5-ASA.30 
Although this study did note a trend towards more AEs in the 
highest dose subgroup (4.8 g per day), no study participants 
discontinued treatment due to AEs. In contrast, both large 
phase III remission induction studies failed to show any dose-
response relationship between MMX mesalamine and AEs. 
Both studies found no signiﬁ  cant difference in the rates of 
AEs between MMX mesalamine and placebo. The majority 
of AEs were mild or moderate. The most common AEs 
were gastrointestinal disorders, including nausea, ﬂ  atulence, 
diarrhea, and worsening of UC, as well as other conditions 
such as headache.
Recent data have conﬁ  rmed an interaction between 5-ASA 
compounds and thiopurines such as azathioprine. While 
the mechanism of this interaction is not entirely elucidated, 
concurrent administration of mesalamine and azathioprine 
appears to signiﬁ  cantly increase levels of 6-thioguanine 
nucleotides, the major active marrow toxic derivative of 
azathioprine.31 Likewise, withdrawal of mesalamine from 
a 5-ASA and thiopurines regimen has been shown in vivo 
to result in signiﬁ  cantly decreased levels of 6-thioguanine 
nucleotides.32 A theoretical risk of dosage toxicity does exist 
with the addition of MMX mesalamine to a drug regimen 
that includes a thiopurine, and appropriate surveillance labs 
and drug levels should be monitored closely.
Patient-focused perspectives such 
as quality of life, patient satisfaction/
acceptability, adherence and uptake
Even the most effective medical therapies in UC are of no 
utility if patients are unable to adhere to the treatment regimen. 
Historically, physicians have notoriously overestimated 
patients’ rates of adherence, a misjudgment that may have 
dire consequences. Studies have shown that as few as 40% 
of patients are adherent to their traditional maintenance UC 
therapy.8 Not surprisingly, patients who are non-adherent to 
their medication (deﬁ  ned as ﬁ  lling fewer than 80% of their 
prescriptions) are over ﬁ  ve times more likely to experience 
a disease ﬂ  are as compared to adherent patients.7
Clearly, adherence to a medication regimen reduces dis-
ease activity. Disease activity in UC, in turn, has been shown 
to be a primary determinant of patients’ general life satisfac-
tion (GLS) and health-related life satisfaction (HRLS).2–4 
Hence it is reasonable to conclude that an easily adhered-to 
UC regimen would directly improve patients’ quality of life 
and overall satisfaction.
But the successful design of a UC regimen that allows 
adherence without compromising efﬁ  cacy has not yet been 
described. Understanding which factors affect patient 
adherence is critical to designing such a regimen. Previous 
literature has identiﬁ  ed male gender, taking more than four 
prescription medications concomitantly, and disease limited 
to the left side of the colon as risk factors for non-adherence.8 
More recently, a survey of 1595 patients with UC receiving 
5-ASA therapy showed the most common reasons for 
non-adherence were “too many pills,” “dosing required too Patient Preference and Adherence 2009:3 91
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many times each day,” “medication too inconvenient,” and 
“forgetting to take medication”.33 These sentiments have 
been echoed elsewhere.34,35 Despite having knowledge of 
these barriers to effective therapy, providers were still limited 
by the half-life and pill burden of traditionally available 
medications.
In an effort to demonstrate improved adherence with a 
smaller pill burden, a small 2003 pilot study compared once-
daily vs conventional dosing of traditional mesalamine.36 
A signiﬁ  cant difference in patient adherence was observed 
(100% vs 70%). Interestingly, once-daily dosing had the 
same rate of disease relapse as the conventional dosing group. 
However, this study was neither designed nor powered to 
evaluate the efﬁ  cacy of once-daily dosing, but rather simply 
to monitor adherence. It conﬁ  rmed that outpatients with UC 
are better able to adhere to a once-daily regimen as compared 
to a regimen with more frequent dosing. However, a major 
obstacle remained the lack of an available drug that combined 
this dosing frequency with proven efﬁ  cacy.
When phase III clinical trial data demonstrated that once-
daily MMX mesalamine was effective in inducing remission 
of active UC, it provided hope that this convenient regimen 
might also be effective in maintaining disease quiescence. 
This would unite the beneﬁ  ts of clinical efﬁ  cacy and ease-of-
use for long-term therapy. As discussed above, one year 
follow-up data have shown MMX mesalamine to be effective 
in maintenance of remission. That study reported that 96% 
of patients enrolled were adherent to their medication 
regimen, having taken more than 80% of their prescribed 
medication.12
While this may appear to be an exciting step towards 
realizing the “holy grail” of medical therapy, it remains 
to be seen if such adherence rates are generalizable to the 
community setting. The 96% adherence rate was obtained in 
a strictly monitored clinical setting, which is well known to 
produce unrealistic adherence rates. However, as seen in the 
2003 pilot study of once-daily mesalamine dosing, adherence 
in the community setting with a once-daily mesalamine 
regimen did yield signiﬁ  cantly improved adherence when 
compared to traditional outpatient regimens. As the use of 
MMX mesalamine increases, more studies of community 
adherence need to be performed in order to evaluate for any 
signiﬁ  cant change from previous rates.
Conclusions, place in therapy
Overall, the existing data support MMX mesalamine as a 
safe and effective once-daily medication for induction and 
maintenance of remission in mild-to-moderate ulcerative 
colitis. Its potential for clinical use is not yet fully realized, and 
may still be limited by hesitation from physicians, patients, 
and the insurance industry.37 Certainly, placebo controlled 
studies directly comparing MMX mesalamine and other 
5-ASA compounds dosed in a once-daily manner must be 
done in order to establish non-inferiority in the maintenance 
setting. Additionally, community adherence studies must be 
performed to evaluate the prospect of MMX mesalamine as 
a breakthrough in convenience and potential for adherence. 
However, initial studies provide compelling evidence that 
MMX mesalamine may represent the ﬁ  rst once-daily oral 
5-ASA therapeutic that provides the clinical efﬁ  cacy and 
safety patients expect, while also eliminating the pill burden 
and inconveniences that have traditionally represented 
formidable barriers to adherence and effective therapy.
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